Sanofi SA

Sanofi’s third-quarter earnings report exceeded expectations, driven by strong sales of its flagship product Dupixent, which surpassed €4 billion in revenue for the first time, and the company reaffirmed its 2025 outlook while signaling optimism f…

Sanofi’s Wayrilz, a groundbreaking BTK inhibitor, has received US approval for the treatment of immune thrombocytopenia, a condition characterized by low platelet count.

Sanofi’s stock price has fluctuated within a stable 52-week range, with a current price of 87.34 EUR and moderate valuation metrics.

Sanofi has navigated market volatility with a steady hand, thanks to its diversified portfolio, commitment to innovation, and recent breakthroughs in treatments for oncology and cardiovascular diseases.

Sanofi’s stock price and valuation metrics suggest a company poised for continued growth and development, with investors closely monitoring its financial performance.

Sanofi’s stock price has taken a hit, but a recent upgrade from JP Morgan to an overweight rating and a target price of 105 euros suggests brighter days ahead for the French pharmaceutical company.

Sanofi has strengthened its neurology pipeline with the acquisition of Vigil Neuroscience, gaining a novel treatment for neurodegenerative diseases, including Alzheimer’s.

Sanofi has acquired the rights to its candidate drug plozasiran in China, a strategic move that could unlock new revenue streams and drive growth for the French pharmaceutical giant.

Sanofi’s second-quarter results exceeded market expectations, driven by strong sales of Dupixent and new medicines, with the company’s stock price expected to increase in the coming period.

Sanofi has exceeded expectations in its second quarter, with a 6% revenue increase and a raised sales growth outlook for 2025, prompting analysts to become increasingly bullish on the company’s stock.